Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lavender scent may sharpen memory in aging brains

NCT ID NCT07688382

Symptom relief Sponsor: China Medical University, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether inhaling lavender aromatherapy for 30 minutes a day, five times a week for 12 weeks can improve memory, thinking, mood, and sleep in older adults with mild cognitive impairment (MCI). Participants will be randomly assigned to receive lavender aromatherapy or a placebo. The goal is to see if this simple, non-drug approach can help slow or improve cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lavender aromatherapy
What this could lead to
If it works, this could offer a simple, drug-free way to boost memory and quality of life for people with mild cognitive impairment.
What could go wrong
This is a small, early-stage trial with 70 participants. The effects may be modest or not last, and lavender may cause mild allergic reactions in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The MCI mentioned in this study meets the diagnostic criteria proposed by the \*Chinese Expert Consensus on the Diagnosis and Treatment of Alzheimer's Disease-Derived Mild Cognitive Impairment (2021)\*: cognitive impairment reported by the patient or an informant, or identified by an experienced clinician; objective evidence of impairment in one or more cognitive domains, with episodic memory impairment being the most common; complex instrumental activities of daily living may be mildly impaired, but the ability to perform basic activities of daily living remains independent; the diagnostic criteria for dementia are not met. 2. MoCA-Beijing version scores were adjusted for education level: ≤13 for junior high school education or below, ≤19 for high school education, and ≤24 for university education or above; MMSE score \>24; ADL score \<23. 3. Age between 60 and 79 years. 4. Normal olfactory function assessed using the "Sniffin' Sticks" test. 5. Ability to communicate normally and complete cognitive assessments. 6. Residing in a senior care facility with no plans to leave within the next 12 weeks. Exclusion Criteria: 1. Presence of other conditions known to affect cognitive function, such as psychiatric disorders (e.g., schizophrenia, depression). 2. History of asthma or any allergic conditions. 3. Use of any prescription medications that may impact cognitive function (including psychotropic drugs and others)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCI are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.